<style face="normal" font="default" size="100%">Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC<sup>+</sup> tumors respond to PD1/PD-L1 blockade therapy</style>

Drupal-HighWire